Faron Pharmaceuticals Oy (LON:FARN, First North:FARON) said its MATINS phase I/II clinical trial has identified another partial response to its cancer drug, Clevegen.
Remember, early-stage trials of this sort are usually only concerned with assessing safety, side-effects, and dosing.
In Part I of the MATINS trial it was discovered the lung metastasis of a melanoma patient shrank by 44% after receiving the Faron drug.
This was a patient that had received three different immune checkpoint inhibitor drugs and had been on an anti-cancer treatment called dabrafenib until December.
While the lung cancer shrank and the biochemical tumour load marker also declined, scans revealed that the patient had brain metastases and therefore the person was removed from the trial.
In future, Faron said it will include what are called baseline brain scans in its trial protocol.
Chief executive, Dr Markku Jalkanen, said he was “very encouraged” to have found a second partial target lesion responder in such a hard to treat group of melanoma sufferers.
The MATINS Part I study was set up to assess 30 patients on five different doses of Clevegen.